主にテクノロジー×ビジネス×イノベーションについて考察・刺激・アイデアなどを

米中激突! ヘルスケア起業家とVCが10/12 JHVSミートアップ「Global」に集う

»

すごいセッションが実現できました。10/10-12 パシフィコ横浜でのジャパン・ヘルスケアベンチャー・サミット(JHVS)の最終日10時からの「JHVSミートアップ - Global」は特筆されます(JHVSサイトで事前登録できます・・無料)。ヘリオス 鍵本忠尚CEOとJohnson & Johnson Innovation 楠淳 氏のプロデュースによる特別企画。なお、JHVSの他のプログラムはこちらをご覧ください

Forefront of US/China Entrepreneurship vs. Japan (米中アントレプレナーシップ最前線、対する日本は?)と題し、次のようなプレゼンとパネル(英語のみ)を予定しています。
Agenda
Investment Environment to Healthcare start-up in US - difference from Japan (10min)
 Shin-Ichiro (Sheen) Komoto, Partner, Eight Roads Venture Japan
Investment Environment to Healthcare start-up in China ? difference from Japan (10min)
 Xiaoyang (Sean) Jiang, CEO, Yafo Captital
My story -- A case in US: Arcturus Therapeutics, Inc (10min)
 Joseph Payne, President and CEO, Arcturus Therapeutics, Inc
My story -- A case in China: HitGen Ltd. (10min)
 Jin Li, President and CEO, HitGen, Ltd.
Panel Discussion (50min)
Facilitator: Dan Wang, Head of Johnson and Johnson Innovation Asia Pacific
Panelists: Sheen Komoto, Sean Jing, Joe Payne, Jin Li
Assembly with audiences (30min)

MC: Tadahisa Kagimoto, CEO, Helios,
Jun Kusunoki, Director, New Ventures Japan, Johnson & Johnson Innovation.

Date/time: October 12th, 2018; 10am- 12pm
Theme: Forefront of US/China Entrepreneurship vs. Japan
Venue: Harbor Lounge A, Pacifico Yokohama, Yokohama, Japan
Aim:
Comparing to the US and China, number of successful start-ups and bioventures in the healthcare sector are fewer in Japan nevertheless there are many cutting edge disruptive science from Japanese academia. What are the reasons behind?
To get some clue, we would offer a fantastic opportunity to meet with the most successful intrepreneurs and venture capitalists from US, China and Japan. In this session, we can learn: 1) investment environment in the US, China as well as in Japan; 2) Successful cases how to start/grow start-up company in US and China. Also, in the panel discussion, we can further discuss: 1) what parts are missing to start/grow startup company; 2) what policies are required to make the healthcare ecosystem more successful in Japan; and etc.
We would encourage all of you to come and join this exciting session to physically meet and discuss with key players!!!

Speakers

Joseph Payne, President & CEO, Arcturus Therapeutics
Joseph Payne is the President and Chief Executive Officer of Arcturus Therapeutics (NASDAQ:ARCT). He has served on Arcturus's Board since its founding in 2013. During his tenure, Arcturus has built a diverse pipeline of seven (7) RNA medicines, and established multiple pharmaceutical partnerships globally with potential value totaling over $2 Billion. Prior to Arcturus, Joseph's background includes successful pharma experience at Merck Research Labs, DuPont Pharmaceuticals, Bristol-Myers Squibb, Kalypsys, and Nitto as evidenced by over 40 publications and patents, and several investigational new drug (IND) clinical candidates. His academic training includes a Bachelor's Degree in Chemistry, magna cum laude from Brigham Young University, a Master of Science in Synthetic Organic Chemistry from the University of Calgary and Executive Training Certification from MIT Sloan School of Management.

Jin Li, Chariman & CEO, HitGen, Ltd
Dr Li holds 28 years biopharmaceutical experience (at Protherics and AstraZeneca), with senior scientific and leadership roles in early stage research; as well as experience in initiating and leading major collaboration, research and outsourcing programmes. Before founding HitGen, he held Global Director positions of Compound Sciences and Computational Sciences at AstraZeneca. This included responsibility for computational chemistry, computational biology and compound collection enhancement. Dr Li completed his BSc at Sichuan University, and PhD in macromolecular sciences at Aston University. He then completed post-doctoral research in theoretical biochemistry at Manchester University, UK. Dr Li is also a Fellow of the Royal Society of Chemistry, the Guest Professor of Sichuan University and the Expert with Outstanding Contribution to Sichuan Province. He and his team have gained lots of rewards from different levels.
 
Xiaoyang (Sean) Jiang, CEO, Yafo Capital

Mr. Jiang is a founding partner and CEO of Shanghai Yafo Capital. He has about 20 years' experience in investment banking, M&A, and investment in both China and Wall Street. Yafo Capital is dedicated to bringing global life science technologies to the Chinese market through licensing or investment. He was the General Manager of ISI Group's China division and the Managing Director of ISI research. Before that, he was a senior research analyst at Roth Capital where he was involved in multiple cross-border transactions. When at Xiangcai Securities, a leading investment bank in Shanghai, Sean was the executive director, responsible for advising foreign institutional investors in China's stock markets.

Mr. Jiang is now a visiting professor at Concordia University (Wisconsin). He received his MBA from Pepperdine University, MA from Fudan University, and BA from Central South University of China. He is a CFA Charter holder.

Sheen Komoto, Partner, Eight Roads Ventures Japan

Sheen leads the Healthcare and Biosciences team at Eight Roads in Japan. He joined following an 18-year career at Mitsui & Co. where he spent 9 years in US, Singapore and Vietnam and was most recently Deputy General Manager, Healthcare Service. BA of Electric Engineering from Tokyo Metropolitan University, Executive Educational Program at INSEAD.

Dan Wang, Head, Johnson and Johnson Innovation, Asia Pacific

Dan Wang, MD, is the Head of Johnson & Johnson Innovation, Asia Pacific. In this role, she is responsible for managing a portfolio of co-investments spanning across all three sectors of Johnson & Johnson and expanding the external networks within the innovation ecosystem.

Dan has over 20 years of experience in the life sciences sector. Prior to joining Johnson & Johnson Innovation, Dan has worked with Becton Dickinson(BD), e-Capital Corporation, Express Scripts and Johnson & Johnson by leading the local and global Research & Development, Medical Affairs and clinical research teams. She also has strong track records in strategic innovation of identifying new product opportunities and external partnerships.

Dan holds MD and MSc degrees from Peking University and she received her MBA from Goizueta Business School, and MPH from Rollins school of Public Health, Emory University, Atlanta in the U.S.

Comment(0)

コメント

コメントを投稿する